Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of blood cancer called T/B-ALL or T/B-LL (types of leukemia or lymphoma affecting white blood cells)
- People whose cancer has come back after treatment or has not responded to treatment, and where no other curative treatment options are available
- People whose major organs (such as heart, liver, and kidneys) are functioning well enough, and who are in a sufficient overall state of health (confirm specific requirements with trial site)
Who may not be able to join:
- People whose cancer has spread to the central nervous system (the brain and spinal cord) at a level classified as "CNS3" (confirm with trial site)
- People who have certain inherited conditions that affect how the body repairs DNA, such as Fanconi anaemia or Bloom syndrome, or people who have Down Syndrome (trisomy 21)
- People who have previously received a treatment that targets a protein called CD127
- People who have an infection that is not currently under control
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eric Schafer, MD, Baylor College of Medicine
Phone: 15153439875
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Treatment-Emergent Adverse Events (TEAEs) at each dose level; Determine the Recommended Phase 2 Dose (RP2D)/ Recommended Dose for Expansion (RDE) of 4A10 as a single agent in patients with R/R ALL/LL.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.